Artificial Intelligence and Cancer Drug Development

Fan Yang, Jerry A. Darsey, Anindya Ghosh, Hong Yu Li, Mary Q. Yang, Shanzhi Wang

Research output: Contribution to journalShort surveypeer-review

Abstract

Background: The development of cancer drugs is among the most focused “bench to bedside activities” to improve human health. Because of the amount of data publicly available to cancer research, drug development for cancers has significantly benefited from big data and Artificial Intelligence (AI). In the meantime, challenges, like curating the data of low quality, remain to be resolved. Objectives: This review focused on the recent advancements and challenges of AI in developing cancer drugs. Methods: We discussed target validation, drug repositioning, de novo design, and compounds' synthetic strategies. Results and Conclusion: AI can be applied to all stages during drug development, and some excellent reviews detailing the applications of AI in specific stages are available.

Original languageEnglish (US)
Pages (from-to)2-8
Number of pages7
JournalRecent Patents on Anti-Cancer Drug Discovery
Volume17
Issue number1
DOIs
StatePublished - Feb 1 2022

Keywords

  • Artificial intelligence
  • deep learning
  • drug design
  • drug discovery
  • machine learning
  • target validation

ASJC Scopus subject areas

  • Oncology
  • Drug Discovery
  • Cancer Research
  • Pharmacology (medical)

Fingerprint

Dive into the research topics of 'Artificial Intelligence and Cancer Drug Development'. Together they form a unique fingerprint.

Cite this